AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Nurix Therapeutics, Inc. Common stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00SDJ8M87
25.34▼ 0.17 (-0.67%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
25.51
Day's Range
24.78 – 25.49
52-Week Range
10.28 – 28.23
Volume
1.9M
Avg Volume
1.9M
Share Statistics
Shares Outstanding
Employees
357
Exchange
XNAS
Listed
2020-07-24
Share count as of September 30, 2026

Nurix Therapeutics, Inc. Common stock (NRIX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Nurix Therapeutics, Inc. Common stock (NRIX)
What is Nurix Therapeutics, Inc. Common stock's Market Cap?
Nurix Therapeutics, Inc. Common stock's Market Cap is $2.8B, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's Enterprise Value?
Nurix Therapeutics, Inc. Common stock's Enterprise Value is $2.0B, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's Trailing P/E?
Nurix Therapeutics, Inc. Common stock's Trailing P/E is 9.4×, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's Price / Sales?
Nurix Therapeutics, Inc. Common stock's Price / Sales is 3.9×, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's EV / Revenue?
Nurix Therapeutics, Inc. Common stock's EV / Revenue is 2.9×, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's EV / EBITDA?
Nurix Therapeutics, Inc. Common stock's EV / EBITDA is 6.9×, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's Revenue (TTM)?
Nurix Therapeutics, Inc. Common stock's Revenue (TTM) is $701.9M, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's Net Income (TTM)?
Nurix Therapeutics, Inc. Common stock's Net Income (TTM) is $294.9M, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's EBITDA?
Nurix Therapeutics, Inc. Common stock's EBITDA is $298.4M, based on as-reported figures from SEC (XBRL) filings.
What is Nurix Therapeutics, Inc. Common stock's Diluted EPS (TTM)?
Nurix Therapeutics, Inc. Common stock's Diluted EPS (TTM) is 2.70, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NRIXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemAug 31, 2026May 31, 2026Feb 28, 2026Nov 30, 2025Aug 31, 2025May 31, 2025Feb 28, 2025Nov 30, 2024Aug 31, 2024May 31, 2024Feb 29, 2024Nov 30, 2023Aug 31, 2023May 31, 2023Feb 28, 2023Nov 30, 2022
Total revenue
YoY growth+8426.3%-79.5%-66.1%+2.2%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue16.9%1141.7%1579.4%712.0%
Income (loss) from operations
% of revenue83.1%-1041.7%-1479.4%-612.0%
Interest and other income, net
Income (loss) before income taxes—
Provision for income taxes—
Net income (loss)
% of revenue81.7%-990.1%-1394.3%-576.1%
Net income (loss) per share, basic (in USD per share)
Net income (loss) per share, diluted (in USD per share)